469 related articles for article (PubMed ID: 11805241)
1. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
[No Abstract] [Full Text] [Related]
2. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
Noseworthy JH
Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
[No Abstract] [Full Text] [Related]
4. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
5. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
6. Immunologic therapy for secondary and primary progressive multiple sclerosis.
Myers LW
Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
[TBL] [Abstract][Full Text] [Related]
7. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
8. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
9. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
10. Current approved options for treating patients with multiple sclerosis.
Rizvi SA; Agius MA
Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis treatment 2001.
Rolak LA
Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
[TBL] [Abstract][Full Text] [Related]
12. How should we proceed with disease-modifying treatments for multiple sclerosis?
Andersson PB; Waubant E; Goodkin DE
Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726
[No Abstract] [Full Text] [Related]
13. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
14. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
Confavreux C; Vukusic S
Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
[No Abstract] [Full Text] [Related]
15. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger J; Freedman M
Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
[No Abstract] [Full Text] [Related]
16. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Sorensen PS; Bertolotto A
Neurology; 2007 Oct; 69(15):1552; author reply 1553. PubMed ID: 17923618
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
19. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
Rieckmann P; Toyka KV
Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
[TBL] [Abstract][Full Text] [Related]
20. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Polman CH; Deisenhammer F; Giovannoni G; Killestein J; Schellekens H
Neurology; 2007 Oct; 69(15):1553-4; author reply 1555. PubMed ID: 17923619
[No Abstract] [Full Text] [Related]
[Next] [New Search]